SCHEMBL4254049

SCHEMBL4254049

NC(CCB(O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 5/20 1.00
ARG2 P78540 6/20 0.72
ARG1 P05089 4/20 0.72
GSR P00390 2/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
CYP1A2 P05177 1/20 0.52
GRIK1 P39086 1/20 0.52
GRM5 P41594 1/20 0.52
GRIA1 P42261 1/20 0.52
GRIA2 P42262 1/20 0.52
GRIA3 P42263 1/20 0.52
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52
GRIA4 P48058 1/20 0.52
GRIN1 Q05586 1/20 0.52
GRIN2A Q12879 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30726883 1.00 GGT1 (1.00) GGT1ARG2ARG1GSRGRM8
SCHEMBL6702428 0.86 ARG2 (0.88) GGT1ARG2ARG1GSRGRM8
SCHEMBL6702426 0.86 ARG2 (0.88) GGT1ARG2ARG1GSRGRM8
SCHEMBL215523 0.84 ARG2 (1.00) GGT1ARG2ARG1GSRGRM8
SCHEMBL215522 0.84 ARG2 (1.00) GGT1ARG2ARG1GSRGRM8
Hydrochloric Acid SCHEMBL29572780 0.82 ARG2 (1.00) GGT1ARG2ARG1GSRGRM8
SCHEMBL6704320 0.81 ARG2 (0.78) GGT1ARG2ARG1GSRGRM8
SCHEMBL6704317 0.81 ARG2 (0.78) GGT1ARG2ARG1GSRGRM8
SCHEMBL28273160 0.80 GGT1 (0.66) GGT1ARG2ARG1GRIK1SLC1A3
SCHEMBL28271686 0.79 GGT1 (0.63) GGT1ARG2ARG1GRIK1SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1361885-B1 USE OF GAMMA-GT INHIBITORS FOR THE TREATMENT OF CHRONIC DEGENERATIVE DISEASES GTX PHARMACEUTICALS GMBH (DE) 2008-04-16 EP claimed
US-20040115284-A1 Use of gamma-GT inhibitors for the treatment of degenerative diseases GTX PHARMACEUTICALS GMBH (DE) 2004-06-17 US claimed
EP-1361885-A1 USE OF $G(G)-GT INHIBITORS FOR THE TREATMENT OF DEGENERATIVE DISEASES GTX Pharmaceuticals GmbH (DE) 2003-11-19 EP claimed
WO-2002066047-A1 USE OF $G(G)-GT INHIBITORS FOR THE TREATMENT OF DEGENERATIVE DISEASES GTX PHARMACEUTICALS GMBH (DE) 2002-08-29 WO claimed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2009043114-A1 ARSENOXIDE COMPOUND AND METHOD OF USE NEWSOUTH INNOVATIONS PTY LIMITED (AU) 2009-04-09 WO disclosed
EP-1361885-B1 USE OF GAMMA-GT INHIBITORS FOR THE TREATMENT OF CHRONIC DEGENERATIVE DISEASES GTX PHARMACEUTICALS GMBH (DE) 2008-04-16 EP disclosed
US-20040115284-A1 Use of gamma-GT inhibitors for the treatment of degenerative diseases GTX PHARMACEUTICALS GMBH (DE) 2004-06-17 US disclosed
EP-1361885-A1 USE OF $G(G)-GT INHIBITORS FOR THE TREATMENT OF DEGENERATIVE DISEASES GTX Pharmaceuticals GmbH (DE) 2003-11-19 EP disclosed
WO-2002066047-A1 USE OF $G(G)-GT INHIBITORS FOR THE TREATMENT OF DEGENERATIVE DISEASES GTX PHARMACEUTICALS GMBH (DE) 2002-08-29 WO disclosed
WO-2002028869-A1 GAMMA-GLUTAMYL TRANSPEPTIDASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH (US) 2002-04-11 WO disclosed